Fundraising Fox
C2N Diagnostics
St. Louis, US · Delaware LLC · 2 known investors
Find your way into C2N Diagnostics
Sign up to see every warm intro you have to C2N Diagnostics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the C2N Diagnostics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
C2N Diagnostics develops and commercializes blood-based diagnostic tests for Alzheimer's disease and other neurodegenerative conditions, using proprietary LC-MS/MS mass spectrometry to detect brain amyloid pathology. Its PrecivityAD, PrecivityAD2, and Precivity-ApoE tests serve health care professionals evaluating patients with cognitive impairment, available across all 50 US states and the District of Columbia.
Founders & leadership
Board
Investors · 2
Also in the syndicate · 2
Reported raises · per SEC filings
Form D private placements$35M disclosed across 2 of 4 rounds · 2023–2026
▶$10MraisedMay 2025 · 1 investors · BiotechnologyRule 506(b)
- Fred MillerDirector
- Dr. Michael GoldblattDirector
- Micah OnixtExecutive Officer
- Dr. David HoltzmanDirector
- Dr. Randall BatemanDirector
- Dr. Joel BraunsteinExecutive Officer, Director
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- May 2025
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
▶$25MraisedSep 2024 · 3 investors · BiotechnologyRule 506(b)
- Dr. David HoltzmanDirector
- Dr. Randall BatemanDirector
- Micah OnixtExecutive Officer
- Dr. Joel BraunsteinExecutive Officer, Director
- Dr. Michael GoldblattDirector
- Offering amount
- $25M
- Amount sold
- $25M
- First sale
- Mar 2024
- Incorporated
- Limited Liability Company, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 2
Companies working in the same space as C2N Diagnostics.
In the news
Frequently asked questions
- What does C2N Diagnostics do?
- C2N Diagnostics develops and commercializes blood-based diagnostic tests for Alzheimer's disease and other neurodegenerative conditions, using proprietary LC-MS/MS mass spectrometry to detect brain amyloid pathology. Its PrecivityAD, PrecivityAD2, and Precivity-ApoE tests serve health care professionals evaluating patients with cognitive impairment, available across all 50 US states and the District of Columbia.
- Who founded C2N Diagnostics?
- C2N Diagnostics was founded by Dr. David Holtzman, Dr. Randall Bateman, Dr. Joel Braunstein.
- How much funding has C2N Diagnostics raised?
- C2N Diagnostics has disclosed $35M raised across 2 of its 4 known rounds.
- Where is C2N Diagnostics headquartered?
- C2N Diagnostics is headquartered in St. Louis, US.